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Dear Editor,
Two studies in 2000 and 2001, both conducted using the UK
General Practice Research Database (GPRD), reported
conflicting results on the potential beneficial effects of statin
use and fracture risk. An extensive reanalysis of the results
showed that selection bias in one study largely explained the
discrepant findings and that the results did not support a
hypothesis of beneficial effects on bone. The reanalysis
showed that the risk of hip fractures was halved almost
instantly after starting statins and waned thereafter, which is
difficult to reconcile with a bone effect. The biological
mechanism assumed in 2000 was that statins affected the
mevolanate pathway as do the bisphosphonates. Rather than
emphasising the summary relative risks (RRs) in the original
statin analyses, the absence of a durable response should
have limited the interpretation of the findings since the data
did not support a biological mechanism for statins to
increase the quality or quantity of bone [1].
Does history repeat itself? On 25 May 2010, the Food and
Drug Administration (FDA) decided to add a warning of a
possible increased risk of fractures to the labelling of proton
pump inhibitors (PPIs), drugs that are widely used for the
treatment of gastroesophageal reflux disease [2]. This
decision was based on the FDA's internal review of seven
epidemiological studies, including two studies that used
GPRD, but again with conflicting results [3, 4]. Two recently
published papers were not included in this review, including
a third GPRD study [5]. The FDA review showed that only
few studies have evaluated the duration of any effect
between use of PPIs and risk of fracture. The two recent
studies in GPRD [5] and the Dutch PHARMO database
(which has been published as an abstract since mid 2009, but
which is now in press in Osteoporosis International) showed
that the association between PPI use and fracture risk at
various fracture sites was highest during the first year of
treatment (a 1.3-fold increased risk of hip fracture), and then
attenuated with prolonged use (with a 0.9-fold increased risk
of hip fracture in patients who had used PPIs for >7 years
[6]). Similar to findings with statins and fracture risk,
selection bias could explain this pattern of risk with duration
of use [1]. These data are not supportive of a hypothesis that
PPIs modify the quality or quantity of bone.
The FDA review considered that the biological mecha-
nisms for an increased risk of fractures with PPIs are not
known. Despite this, the FDA review concluded that the
available data suggested a possible increased risk of
fractures with PPI use. In our view, evidence for drug
effects should not be used on an assessment of deviations of
summary RRs from unity but rather on an assessment on
whether specific hypotheses of biological mechanisms of
drug effects are supported by evidence. Given the weak and
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studies, but also for a pharmacological effect of PPIs on
bone mineral density in humans, we feel that the label
change of PPIs is premature.
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